Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Social Media Sites Struggle For Audience Under Shadow Of Potential FDA Action

Executive Summary

Drug makers are using YouTube videos and other social media channels to broadcast their expertise and initiatives; Amgen differentiates its biologic manufacturing from biosimilars, J&J teams up with Huffington Post to tell stories about motherhood, and Pfizer tries to conduct a clinical trial online.

You may also be interested in...



Third-Party Social Media: Firms Should Not Be Selective In Corrections

FDA’s draft guidance on correcting independent third-party misinformation about drugs and devices advises companies to address exaggerated efficacy claims as well as incorrect risk information.

Third-Party Social Media Sites: Firms Should Not Be Selective In Corrections

FDA’s draft guidance on correcting independent third-party misinformation about Rx drugs and devices advises firms to address exaggerated efficacy claims as well as incorrect risk information.

Wikipedia Disease Information Worth Monitoring By Pharma Companies, IMS Says

An analysis of Wikipedia page visits over the last two years shows that rarer diseases had a higher frequency of visits than many more common conditions, IMS Institute for Health Informatics says.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel